We engage patient populations to identify opportunities for intelligently improved products.
The starting point for all our projects is an opportunity to address the unmet needs of specific populations of patients.
Our strategy is simple:
1. Low Cost
2. Low Risk
3. Fast Market Entry
At the core of our offering is a development process which synthesizes the core drivers of generic and proprietary pharmaceutical models. Like generic companies, we base our products on known active ingredients used in proven diseases. Also like generics, our costs are kept extremely low.
The difference between Small Pharma and a classic generic model is that our products are clinically differentiated and defensible. We know how to generate effective IP from low cost development programmes. This allows us to protect our commercial interests and still deliver value to our patients.